Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

Phase 1

Recruiting

Conditions: Stage IIIB Vulvar Cancer AJCC v8
Stage II Vulvar Cancer AJCC v8
Stage IIIA Vulvar Cancer AJCC v8
Stage IIIC Vulvar Cancer AJCC v8
Stage III Vulvar Cancer AJCC v8
Stage IVA Vulvar Cancer AJCC v8

Interventions: Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Drug: Nelfinavir

First Posted Date: 2019-11-20

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT04169763

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Phase 3

Terminated

Conditions: Biliary Tract Cancer

Interventions: Drug: NUC-1031
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2019-11-15

Last Posted Date: 2023-05-24

Lead Sponsor: NuCana plc

Target Recruit Count: 773

Registration Number: NCT04163900

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States
🇺🇸
The Research Foundation for The State University of New York, Stony Brook, New York, United States
🇺🇸
The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

and more 122 locations

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Phase 2

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Toripalimab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-fu

First Posted Date: 2019-11-15

Last Posted Date: 2019-11-15

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 90

Registration Number: NCT04164238

Locations: 🇨🇳
Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Early Phase 1

Recruiting

Conditions: Lymphoma, B-Cell

Interventions: Drug: Rituximab Injection
Drug: Tafasitamab
Drug: Venetoclax
Drug: Rituximab SC
Drug: Gemcitabine
Drug: Cisplatin
Drug: Dexamethasone
Drug: Glofitamab

First Posted Date: 2019-11-13

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 18

Registration Number: NCT04161248

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
The Jewish General Hospital, Montreal, Quebec, Canada

and more 1 locations

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Nivolumab
Drug: Low dose doxorubicin
Drug: Cisplatin

First Posted Date: 2019-11-12

Last Posted Date: 2022-03-22

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 52

Registration Number: NCT04159818

Locations: 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Phase 3

Terminated

Conditions: Pleural Biphasic Mesothelioma
Pleural Epithelioid Mesothelioma
Stage I Pleural Malignant Mesothelioma AJCC v8
Stage IA Pleural Malignant Mesothelioma AJCC v8
Stage IB Pleural Malignant Mesothelioma AJCC v8
Stage II Pleural Malignant Mesothelioma AJCC v8
Stage IIIA Pleural Malignant Mesothelioma AJCC v8

Interventions: Drug: Carboplatin
Drug: Cisplatin
Procedure: Decortication
Drug: Pemetrexed
Radiation: Intensity-Modulated Radiation Therapy
Drug: Pemetrexed Disodium
Procedure: Pleurectomy
Other: Quality-of-Life Assessment
Radiation: Pencil Beam Scanning
Other: Questionnaire Administration

First Posted Date: 2019-11-08

Last Posted Date: 2023-11-28

Lead Sponsor: NRG Oncology

Target Recruit Count: 16

Registration Number: NCT04158141

Locations: 🇨🇦
The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇺🇸
Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 24 locations

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Phase 2

Active, not recruiting

Conditions: Chemotherapy
Hypopharyngeal Carcinoma
Immunotherapy

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: Capecitabine
Drug: Camrelizumab

First Posted Date: 2019-11-07

Last Posted Date: 2023-08-09

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 51

Registration Number: NCT04156698

Locations: 🇨🇳
Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China

A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)

Phase 1

Completed

Conditions: Mesothelioma

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2019-11-06

Last Posted Date: 2024-03-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 19

Registration Number: NCT04153565

Locations: 🇯🇵
Kanagawa Cancer Center ( Site 0004), Yokohama, Kanagawa, Japan
🇯🇵
JOHAS Okayama Rosai Hospital ( Site 0002), Okayama, Japan
🇯🇵
Hyogo College of Medicine Hospital ( Site 0003), Nishinomiya, Hyogo, Japan

and more 1 locations

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: IMRT
Drug: Cisplatin

First Posted Date: 2019-10-23

Last Posted Date: 2019-10-23

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 346

Registration Number: NCT04136886

Locations: 🇨🇳
WangHanYu, Guangzhou, Guangdong, China

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3

Active, not recruiting

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: TAK-788
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2019-10-16

Last Posted Date: 2024-11-28

Lead Sponsor: Takeda

Target Recruit Count: 354

Registration Number: NCT04129502

Locations: 🇮🇹
AORN Dei Colli- Ospedale Monaldi Napoli, Napoli, Campania, Italy
🇺🇦
Private Enterprise Private Manufacturing Company Acinus, Kropyvnytskyi, Ukraine
🇨🇳
Icahn School of Medicine at Mount Sinai, Beijing, China

and more 129 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy